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Julia Snowball, Graham Handley, Richard F Logan, Sandra Rainbow, Steve Smith, Mary C Thomas, Nicholas Counsell, Steve Morris, 
Stephen W Duﬀ y, Allan Hackshaw, Sue Moss, Wendy Atkin, Rosalind Raine
Summary
Background Uptake in the national colorectal cancer screening programme in England varies by socioeconomic 
status. We assessed four interventions aimed at reducing this gradient, with the intention of improving the health 
beneﬁ ts of screening.
Methods All people eligible for screening (men and women aged 60–74 years) across England were included in 
four cluster-randomised trials. Randomisation was based on day of invitation. Each trial compared the standard 
information with the standard information plus the following supplementary interventions: trial 1 (November, 2012), 
a supplementary leaﬂ et summarising the gist of the key information; trial 2 (March, 2012), a supplementary narrative 
leaﬂ et describing people’s stories; trial 3 (June, 2013), general practice endorsement of the programme on the 
invitation letter; and trial 4 (July–August, 2013) an enhanced reminder letter with a banner that reiterated the 
screening oﬀ er. Socioeconomic status was deﬁ ned by the Index of Multiple Deprivation score for each home address. 
The primary outcome was the socioeconomic status gradient in uptake across deprivation quintiles. This study is 
registered, number ISRCTN74121020.
Findings As all four trials were embedded in the screening programme, loss to follow-up was minimal (less than 
0·5%). Trials 1 (n=163 525) and 2 (n=150 417) showed no eﬀ ects on the socioeconomic gradient of uptake or overall 
uptake. Trial 3 (n=265 434) showed no eﬀ ect on the socioeconomic gradient but was associated with increased overall 
uptake (adjusted odds ratio [OR] 1·07, 95% CI 1·04–1·10, p<0·0001). In trial 4 (n=168 480) a signiﬁ cant interaction was 
seen with socioeconomic status gradient (p=0·005), with a stronger eﬀ ect in the most deprived quintile (adjusted 
OR 1·11, 95% CI 1·04–1·20, p=0·003) than in the least deprived (1·00, 0·94–1·06, p=0·98). Overall uptake was also 
increased (1·07, 1·03–1·11, p=0·001).
Interpretation Of four evidence-based interventions, the enhanced reminder letter reduced the socioeconomic 
gradient in screening uptake, but further reducing inequalities in screening uptake through written materials alone 
will be challenging.
Funding National Institute for Health Research.
Copyright © Wardle et al. Open Access article distributed under the terms of CC BY.
Introduction
Colorectal cancer is the fourth most common cause of 
cancer death worldwide,1 and the second most common 
in the UK.2 Screening by testing for occult blood in stools 
reduces mortality.3 In England, an organised colorectal 
cancer screening programme, the Bowel Cancer 
Screening Programme (BCSP), began in 2006, and oﬀ ers 
guaiac faecal occult blood testing (gFOBT) every 2 years 
for people aged 60–74 years (previously up to 69 years).
The UK cancer screening programmes are run by the 
National Health Service (NHS) with no ﬁ nancial costs 
to participants. This approach minimises inequity in 
the delivery of screening, but uptake for all the 
programmes shows a gradient by socioeconomic 
status.4,5 The strongest gradient is for colorectal cancer 
screening: from the ﬁ rst 2·6 million gFOBT invitations 
in 2006–09, uptake was 61% in the least deprived 
quintile of residential areas and only 35% in the most 
deprived quintile.6
Proposed explanations for reduced uptake of screening 
in more deprived groups include factors such as stress, 
low social support, and competing life demands.7 These 
factors are diﬃ  cult to address through the screening 
programme. Literacy might also play an important part 
in uptake because information is delivered entirely 
through mailed written communications.8 Eligible adults 
are sent an invitation letter from their nearest regional 
screening hub, accompanied by a 13-page information 
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booklet that covers complex issues such as risks and 
beneﬁ ts (numerical information) that are designed to 
facilitate informed decision making. Comprehension of 
the screening oﬀ er, therefore, might be challenging in 
the most deprived areas in England, where up to half of 
people are either functionally illiterate or have only basic 
literacy and struggle with statistics.9
The screening hubs are required to use the standard 
information booklet, but each can provide a limited 
amount of extra material to improve presentation of the 
screening oﬀ er. Additionally, a few words can be added 
to the standard invitation and reminder letters. The 
ASCEND project was designed to test four diﬀ erent 
supplements to the screening information materials 
aimed at modifying inequality in screening uptake. 
Various studies have aimed to increase cancer screening 
uptake, but have been done across the whole 
population10–12 or in low-income groups,13 whereas 
ASCEND was speciﬁ cally designed to assess the 
socioeconomic status gradient. The interventions tested 
in ASCEND had a strong theoretical rationale for use 
based on evidence of improving screening uptake in low 
socioeconomic status groups.14,15 The materials 
developed for two of the trials had also been pretested in 
the early stages of the programme for eﬀ ects on 
understanding and motivation.16–20 The four trials were 
embedded within the routine delivery of the screening 
programme. The protocol of this trial is available on the 
trial website.
Methods
Study design and population
We did four separate, two-arm, cluster-randomised 
controlled trials that involved individuals eligible to 
receive routine invitations from the BCSP for screening 
(ﬁ gures 1–4). The trial designs used time-deﬁ ned cluster 
Research in context 
Evidence before this study
We searched the Ovid MEDLINE, PsycINFO, and Embase 
databases for reports on randomised controlled trials assessing 
interventions to increase uptake of cancer screening, published 
between 1980 and 2014, and addressing socioeconomic status. 
We used the search string “Neoplasm/ OR cancer OR neoplas* OR 
onco* OR carcinoma AND Mass screening/ OR screen* OR test OR 
detect* OR mass screening OR cancer screening AND 
Intervention studies/ OR intervention stud* OR stud* OR 
strateg* OR promot* OR initiative* OR behavio* OR behavio* 
change AND Patient acceptance of health care/ OR patient 
compliance/ OR attend* OR uptake OR utili?* OR particip* OR 
complian* OR accept* OR adher* AND breast neoplasms/ OR 
breast OR mammogra* OR uterine cervical neoplasms/ OR 
cervical OR cervix OR colorectal neoplasms/ OR colorectal OR 
bowel OR colon OR rectal OR CRC AND Healthcare Disparities/ OR 
Health Status Disparities/ OR disparit* OR education OR social 
class OR social status OR depriv* OR income OR socioeconomic 
OR socio economic”.  The search retrieved 103 articles addressing 
socioeconomic inequality, but none used reduction of inequality 
as the primary endpoint. 
Added value of this study
We identiﬁ ed no previous studies that used a randomised 
controlled design to test the eﬃ  cacy of interventions designed 
speciﬁ cally to reduce the socioeconomic status gradient in 
screening uptake without compromising overall uptake. Our 
trials assessed diﬀ erent ways to increase the visibility and 
salience of a national colorectal cancer screening programme, 
for which invitations are mailed every 2 years to all people aged 
60–74 years in England. Because the goal was to identify 
interventions that could be easily implemented, all the trials 
were embedded in the routine call and recall system of the 
English Bowel Cancer Screening Programme (BCSP). This 
approach also eliminated any selection bias associated with a 
research study, and provided access to objective data on 
screening uptake. All four interventions were supported by 
evidence of eﬃ  cacy in other contexts or pilot data obtained by 
our group. The gist and narrative leaﬂ ets, designed to provide 
information understandable for people with poor literacy, had 
no eﬀ ects. By contrast, invitation letters showing general 
practice endorsement and enhanced reminder letters improved 
overall uptake. Enhanced reminder letters also signiﬁ cantly 
reduced the socioeconomic status gradient. The negative 
results with the leaﬂ ets might have been due to the increase in 
the total mass of information in the mailing. The changes that 
could be made to the oﬃ  cial letters were limited. The eﬀ ects of 
the enhanced reminder letter might, therefore, have been due 
to increased visibility because the reminder mailing included 
only one letter. These results highlight the importance of doing 
trials in a real-life context to discover what can be achieved with 
minimum intervention.
Implications of all the available evidence
Inequality in uptake is an important limitation of cancer 
screening programmes, even with systems that ensure 
equitable delivery of invitations or with home-based screening 
tests that avoid the barrier of clinic attendance. The main 
ﬁ nding from the four ASCEND trials is that reduction in 
inequality is extremely diﬃ  cult with use of downstream 
approaches in an organised screening programme. The 
signiﬁ cant reduction in socioeconomic status gradient achieved 
with the enhanced reminder letter might lead to improved 
equity at no further cost. Additionally, we found a high level of 
general practice support for the endorsement trial, which raised 
overall uptake, and, therefore, adding such endorsement to the 
reminder letter might increase this eﬀ ect further. The negative 
results with two of our interventions highlight the challenges of 
communicating eﬀ ectively with people with poor literacy who 
need to make decisions based on medical information.
For the trial protocol see 
http://www.ucl.ac.uk/dahr/
research-pages/ascend
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randomisation to usual care (standard information and 
letter [control]) or the intervention (supplemented 
information or letter). The interventions were designed 
to be implemented within the routine procedures of the 
BCSP, which are covered by Health and Social Care 
Information Centre (HSCIC) approval in relation to 
patient-identiﬁ able data. We obtained ethics approval for 
all trials from the National Research Ethics Service 
Committee London-Harrow.
At any time, about 9 million adults in England are 
eligible for gFOBT through the BCSP. The programme 
is coordinated by ﬁ ve regional screening hubs. All 
ﬁ ve hubs were included in the study. People in each 
region and registered with a general practitioner are 
eligible for screening from age 60 years, and biennially 
thereafter up to and including age 74 years. Unless 
individuals have explicitly opted out of screening, all 
eligible people are sent invitation letters and screening 
information by their regional hub. Thus every individual 
scheduled to be invited during the study periods was 
eligible for inclusion.
8–10 days after the initial invitation letter, recipients 
are sent gFOBT kits and instructions. Individuals are 
asked to collect two samples from each of three separate 
bowel motions, and to return the completed kit to the 
regional hub, in a prepaid envelope, for processing. If 
kits are deemed to be spoilt, have a technical failure, or 
yield an unclear result, a repeat gFOBT kit is sent. If a 
recipient does not respond, a reminder letter is sent 
4 weeks from the time of the initial invitation. If there is 
no response after a further 13 weeks, the individual’s 
“screening episode” is closed for that period. If gFOBT 
yields an abnormal result, the person is referred to 
his or her local screening centre for diagnostic 
investigations.
Trial 1: gist leaﬂ et
The gist leaﬂ et (appendix) was a simpliﬁ ed version of 
the screening information designed to be understood 
by readers with low literacy, numeracy, or both. This 
approach was informed by psychological theory21 and 
evidence gained predominately in the USA and in 
groups with low socioeconomic status or poor literacy. 
The data show that presenting complex information in 
simpliﬁ ed formats improves patients’ satisfaction, 
comprehension, and decision making and leads to 
improved behavioural outcomes (eg, adherence to 
prescription regimens).14 During the development of 
this leaﬂ et we were also mindful of guidelines on 
informed choice.22 We had previously done structured 
interviews to identify areas of the standard information 
booklet susceptible to being misunderstood and used 
this information to design the gist leaﬂ et. The eﬀ ects of 
the leaﬂ et on comprehension were assessed in cognitive 
interviews and a trial in primary care, which showed 
improved comprehension compared with the standard 
information.19,20
Trial 2: narrative leaﬂ et
Narrative information is recognised as an eﬀ ective 
communication aid for individuals with poor literacy.23 
The narrative leaﬂ et (appendix) was created on the 
basis of information obtained in interviews with people 
who had participated in the BCSP. Material was selected 
to reﬂ ect screening outcomes: a normal gFOBT result, 
polyp removal, and screen-detected colorectal cancer. 
We tested the eﬃ  cacy of the leaﬂ et in a trial in primary 
care, in which respondents reported being more 
inclined to take part in screening than with standard 
information.13
Trial 3: general practice endorsement
International evidence shows that screening invitations 
sent by individuals’ family doctors improve uptake in 
groups with low socioeconomic status.11,14–16 BCSP 
invitation letters are sent from the hubs, but there is 
space on the letter to mention the support of the general 
practice with which an individual is registered, although 
not the named general practitioner. We created a general 
practice endorsement that appeared as a banner across 
the invitation letter (appendix). We sought consent from See Online for appendix
Figure 1: Trial 1 proﬁ le (gist leaﬂ et)
IMD=Index of Multiple Deprivation.
163 525 individuals eligible
133 excluded (missing IMD data)
163 525 individuals randomised
79 104 allocated to receive standard information 
78 971 individuals included in analysis
138 excluded (missing IMD data)
84 283 individuals included in analysis
84 421 allocated to receive standard information 
 with added gist leaflet 
Figure 2: Trial 2 proﬁ le (narrative leaﬂ et)
IMD=Index of Multiple Deprivation. 
150 417 individuals eligible
274 excluded (missing IMD data)
150 417 individuals randomised
76 695 allocated to receive standard information  
76 421 individuals included in analysis
272 excluded (missing IMD data)
73 450 individuals included in analysis
73 722 allocated to receive standard information 
 with added narrative leaflet 
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all practices in England (n=8142), in collaboration with a 
primary care advisory group and HSCIC, by sending 
each one a written invitation to be part of the trial, 
followed up by reminders 4 and 8 weeks later. Permission 
to link the practice address to the invitation was granted 
by 6480 (80%) of practices.
Trial 4: enhanced reminder letter
Reminders have a slight impact on uptake, including in 
very-low-income groups.13,15 They also provide an 
opportunity to restate the screening oﬀ er. We created 
an enhanced reminder letter that was aimed speciﬁ cally 
at individuals who had not responded to the initial 
invitation. A simple restatement of the screening oﬀ er 
was made in a short paragraph added to the end of the 
standard letter, and a banner was added to the start of 
the letter that said “A reminder to you” (appendix). The 
oﬀ er restatement text had been reﬁ ned through a series 
of focus groups and a review of reminder-related 
queries made by patients to the BCSP’s telephone 
helpline.
Randomisation
Randomisation was based on day of invitation, with “day 
within hub” constituting the randomisation unit. Trials 1 
and 2 were run over 10 consecutive days in November, 
2012, and March, 2013, respectively. Trials 3 and 4 were run 
over 20 consecutive days in June to July, 2013, and July to 
August, 2013, respectively. 2 weeks before the start of each 
intervention, a random number sequence was generated 
with a continuous random number for each hub day, and 
numbers higher than the median were allocated to the 
intervention groups and those lower than the median to 
the control groups. For trials 1 and 2, randomisation 
schedules were created and sent to a printing company 
(Real Digital International, Croydon, UK), for the Southern, 
London, and Eastern hubs, and to the in-house invitation 
service for the North East and Midlands and North West 
hubs. For trials 3 and 4, randomisation was done through 
the Bowel Cancer Screening System, which identiﬁ es the 
eligible population for screening in each hub. For trial 3 
this system was modiﬁ ed to enable selection of invitees 
who belonged to general practices that had agreed to 
endorse the BCSP before the creation of the invitation 
letters. Although masking of hubs was not possible, there 
was no direct contact between hub staﬀ  sending the 
invitations or reminders and invitees. Each study group 
was unaware of the materials received by the other study 
groups unless members of the same household received 
diﬀ erent invitation types or a person had been invited 
previously.
Outcome measures
The primary outcome was socioeconomic status gradient 
in screening uptake over quintiles of Index of Multiple 
Deprivation (IMD). We deﬁ ned screening uptake as the 
proportion of routinely invited individuals that returned 
gFOBT kits within 18 weeks of being sent invitations that 
led to an result of normal or abnormal (with clinical 
referral for prosepctive colonoscopy) by the date of data 
extraction (18 weeks after the last day of the intervention). 
We used the English IMD 2010 score associated with 
home postcodes to classify socioeconomic status.24 IMD is 
an area-based measure that combines income, 
employment, health and disability, education, skills and 
training, barriers to housing and services, crime, and 
living environment, into a deprivation score. The scores 
are assigned to small geographical areas termed lower-
layer super output areas, of which there are 32 844 in 
England, each covering about 1500 individuals. Each 
recipient’s postcode was linked to the relevant lower-layer 
super output area. The IMD scores were grouped into 
quintiles based on national distributions with use of 
predeﬁ ned national cutoﬀ s.
The age and sex of each recipient were obtained from 
the BCSP database. We gathered information on whether 
each individual was being invited for the ﬁ rst time 
(prevalent ﬁ rst-time episode), being sent a biennial 
invitation having previously not responded (prevalent 
Figure 3: Trial 3 proﬁ le (general practice endorsement)
IMD=Index of Multiple Deprivation.
265 434 individuals eligible
562 excluded (missing IMD data)
265 434 individuals randomised
134 011 allocated to receive standard information  
133 449 individuals included in analysis
547 excluded (missing IMD data)
130 876 individuals included in analysis
131 423 allocated to receive standard 
 information with added general practice 
 endorsement banner in letter
Figure 4: Trial 4 proﬁ le (enhanced reminder letter)
IMD=Index of Multiple Deprivation.
168 480 individuals eligible
411 excluded (missing IMD data)
168 480 individuals randomised
90 413 allocated to receive standard reminder 
 letter 
90 002 individuals included in analysis
328 excluded (missing IMD data)
77 739 individuals included in analysis
78 067 allocated to receive standard reminder 
 letter with added banner and text
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episode), or being sent a biennial invitation having been 
screened before (incident episode).
Secondary outcomes were the median number of days 
to return the gFOBT kit and the proportion of spoilt and 
undelivered test kits, by intervention and IMD quintile. 
We also assessed the marginal cost per additional person 
receiving each intervention, calculated with actual costs 
incurred during the study and valued according to 
market prices.
Statistical analysis
Target sample sizes for each trial were estimated to detect 
an average increase in uptake of 3 percentage points, 
based on 1 percentage point increase in the least deprived 
quintile and 5 percentage points in the most deprived 
quintile, with 90% power and p<0·05. The ﬁ nal 
calculation was based on the demographic composition 
of the hub that required the largest sample size (Midlands 
and North West). Because invitations were randomised 
by day, but the number of invitations sent per day varies, 
we applied an inﬂ ation factor of 1·7 to ensure that the 
sample size would confer adequate statistical power. We 
calculated, therefore, that 46 000 individuals (23 000 per 
group) would be needed for each of trials 1 and 2. 
However, due to the volume of invitations sent out 
each week, this target would have been achieved within 
5 days of invitations, and because small numbers of 
clusters increase the risk of bias25 we had speciﬁ ed 10-day 
intervention periods. The ﬁ nal sample size for each of 
these trials, therefore, was 140 000–160 000 individuals. 
The estimated sample size for trial 3 (84 000) assumed 
agreement from 30% of practices and, therefore, the 
required sample size was increased by a factor of 100/30 
to a target of 280 000. To achieve this sample size would 
need 14 days of sending invitations, but we had allowed 
20 days. The target sample size for trial 4 was 140 000, 
which reﬂ ected the fact that the daily number of 
reminders is substantially lower than ﬁ rst invitations.
The intervention periods for trials 3 and 4 overlapped 
because of initial interest in using a factorial design to 
investigate the combined eﬀ ect of adding the general 
practice endorsement to the enhanced reminder letter as 
well as the initial invitation. Owing to space constraints 
on the reminder letter, however, we could not proceed 
with this plan, but it meant that some individuals in 
trial 3 who did not respond to their invitation within 
28 days were included in trial 4.
The primary outcome was analysed by logistic 
regression. Odds ratios (ORs), p values, and 95% CIs 
were calculated with conservative variance estimation to 
Trial 1 Trial 2 Trial 3 Trial 4
Standard 
information and 
gist leaﬂ et 
(n=84 283)
Standard 
information 
(n=78 791)
Standard 
information and 
narrative leaﬂ et 
(n=73 450)
Standard 
information 
(n=76 421)
GP endorsed 
invitation letter 
(n=130 876)
Standard letter 
(n=133 449)
Enhanced reminder 
letter (n=77 739)
Standard letter 
(n=90 002)
Age (years) 66 (59–74) 66 (59–74) 65 (59–74) 65 (59–74) 65 (59–74) 65 (59– 74) 65 (59–74) 64 (59–74)
Sex
Female 43 195 (51·2%) 40 671 (51·4%) 37 937 (51·5%) 39 086 (51·0%) 66 986 (51·0%) 68 591 (51·2%) 37 747 (48·4%) 43 574 (48·2%)
Male 41 226 (48·8%) 38 433 (48·6%) 35 785 (48·5%) 37 609 (49·0%) 64 437 (49·0%) 65 420 (48·8%) 40 320 (51·6%) 46 839 (51·8%)
Screening episode
Prevalent ﬁ rst time 13 034 (15·4%) 12 410 (15·7%) 15 281 (20·7%) 12 510 (16·3%) 22 287 (17·0%) 23 582 (17·6%) 14 483 (18·6%) 21 271 (23·5%)
Prevalent 26 368 (31·2%) 24 551 (31·0%) 22 209 (30·1%) 22 892 (29·8%) 40 441 (30·8%) 40 295 (30·1%) 39 862 (51·1%) 43 329 (47·9%)
Incident 45 019 (53·3%) 42 143 (53·3%) 36 232 (49·1%) 41 293 (53·8%) 68 695 (52·3%) 70 134 (52·3%) 23 722 (30·4%) 25 813 (28·6%)
Programme 
administrative hub
1 22 469 (26·6%) 24 369 (30·8%) 21 421 (29·1%) 21 118 (27·5%) 35 993 (27·4%) 34 598 (25·8%) 22 051 (28·2%) 25 490 (28·2%)
2 20 651 (24·5%) 21 004 (26·6%) 20 667 (28·0%) 16 723 (21·8%) 31 760 (24·2%) 40 550 (30·3%) 19 131 (24·5%) 23 107 (25·6%)
3 7416 (8·8%) 6636 (8·4%) 8509 (11·5%) 8795 (11·5%) 11 818 (9·0%) 13 255 (9·9%) 10 809 (13·8%) 10 385 (11·5%)
4 13 614 (16·1%) 12 858 (16·3%) 13 053 (17·7%) 12 900 (16·8%) 21 272 (16·2%) 21 439 (16·0%) 12 291 (15·7%) 12 796 (14·2%)
5 20 271 (24·0%) 14 237 (18·0%) 10 072 (13·7%) 17 159 (22·4%) 30 580 (23·3%) 24 169 (18·0%) 13 785 (17·7%) 18 635 (20·6%)
IMD quintile*
1 (least deprived) 19 055 (22·6%) 18 554 (23·5%) 17 027 (23·2%) 17 073 (22·3%) 30 350 (23·1%) 31 381 (23·4%) 15 933 (20·4%) 18 928 (20·9%)
2 19 787 (23·5%) 18 295 (23·2%) 16 517 (22·5%) 17 675 (23·1%) 30 952 (23·6%) 31 340 (23·4%) 16 594 (21·3%) 19 446 (21·5%)
3 18 320 (21·7%) 15 993 (20·3%) 15 287 (20·8%) 16 161 (21·1%) 27 950 (21·3%) 28 181 (21·0%) 16 092 (20·6%) 18 286 (20·2%)
4 14 747 (17·5%) 13 469 (17·1%) 12 897 (17·6%) 13 385 (17·5%) 22 450 (17·1%) 23 007 (17·2%) 14 679 (18·8%) 16 853 (18·6%)
5 (most deprived) 12 374 (14·7%) 12 660 (16·0%) 11 722 (16·0%) 12 127 (15·9%) 19 174 (14·6%) 19 540 (14·6%) 14 441 (18·5%) 16 489 (18·2%)
Score missing 138 133 272 274 547 562 328 411
Data are median (range) or number (%). GP=general practice. IMD=Index of Multiple Deprivation. *Quintile categories were based on national cutoﬀ s.26
Table 1: Baseline characteristics of trial population
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allow for the potential clustering eﬀ ects, and were 
controlled for hub, age, sex, and screening round.25,26 
The conservative variance analysis allowed for 
correlation of individuals within randomisation clusters 
but not between clusters, and used the Huber-White 
information sandwich method to estimate variance.27,28 
The primary outcome was tested by the two-factor 
interaction term between intervention group and IMD 
quintile. Analyses were done on an intention-to-treat 
basis. Analyses were done with SAS version 9.3 and 
Stata version 12.1. This study is registered, number 
ISRCTN74121020.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had ﬁ nal responsibility for 
the decision to submit for publication. 
Results
Baseline characteristics were well balanced for each trial 
and showed that the populations were representative of 
that served by the BCSP (table 1).6 Overall uptake per 
study was 57·4%, 57·7%, 57·9%, and 25·4% in trials 1, 2, 
3, and 4, respectively; the proportion is low in trial 4 
because it only targeted individuals who had not 
responded within 4 weeks of the invitation letter. In all 
trials, uptake was strongly and negatively associated with 
deprivation, with the diﬀ erence between the least and 
most deprived quintiles in each control arm ranging 
from 20 to 24 percentage points (table 2).
In trial 1, uptake was similar in the intervention and 
control groups and the least and the most deprived 
quintiles (table 2). The socioeconomic status gradient in 
screening uptake did not diﬀ er by IMD quintile and no 
signiﬁ cant increase was seen in overall uptake 
(table 3, appendix). The median number of days to return 
the test kit was 23 (range 12–126) in the intervention 
group and 22 (11–126) in the control group. Median 
Number (%) in trial 1 Number (%) in trial 2 Number (%) in trial 3 Number (%) in trial 4
Standard 
information and 
gist leaﬂ et 
(n=84 283)
Standard 
information 
(n=78 791)
Standard 
information and 
narrative leaﬂ et 
(n=73 450)
Standard 
information 
(n=76 421)
GP endorsed 
invitation letter 
(n=130 876)
Standard letter 
(n=133 449)
Enhanced reminder 
letter (n=77 739)
Standard letter 
(n=90 002)
Adequately screened 
(overall)
48 653 (57·6%) 45 290 (57·3%) 41 822 (56·7%) 44 904 (58·5%) 76 520 (58·2%) 77 122 (57·5%) 20 166 (25·8%) 22 712 (25·1%)
Age (years)
60–64 19 727 (54·9%) 18 200 (54·2%) 18 264 (53·3%) 19 014 (55·2%) 33 331 (55·9%) 33 480 (54·8%) 10 251 (26·7%) 12 229 (26·1%)
65–69 18 657 (60·8%) 17 346 (61·1%) 14 673 (60·9%) 16 673 (62·4%) 27 382 (61·0%) 27 466 (60·5%) 6674 (26·8%) 6898 (24·8%)
70–74 10 269 (57·7%) 9744 (56·9%) 8885 (57·9%) 9217 (59·2%) 15 807 (58·7%) 16 176 (58·8%) 3241 (21·9%) 3585 (22·6%)
Sex
Female 25 585 (59·2%) 24 017 (59·1%) 22 499 (59·3%) 23 811 (60·9%) 40 707 (60·8%) 41 290 (60·2%) 10 267 (27·2%) 11 511 (26·4%)
Male 23 068 (56·0%) 21 273 (55·4%) 19 323 (54·0%) 21 093 (56·1%) 35 813 (55·6%) 35 832 (54·8%) 9899 (24·5%) 11 201 (23·9%)
Screening episode
Prevalent ﬁ rst time 6466 (49·6%) 5981 (48·2%) 7678 (50·2%) 6231 (49·8%) 11 465 (51·4%) 11 646 (49·4%) 3739 (25·8%) 5398 (25·4%)
Prevalent 3836 (14·5%) 3479 (14·2%) 3113 (14·0%) 3284 (14·3%) 5675 (14·0%) 5357 (13·3%) 2394 (6·0%) 2329 (5·4%)
Incident 38 351 (85·2%) 35 830 (85·0%) 31 031 (85·6%) 35 389 (85·7%) 59 380 (86·4%) 60 119 (85·7%) 14 033 (59·2%) 14 985 (58·1%)
IMD quintile*
1 (least deprived) 12 547 (65·8%) 12 178 (65·6%) 11 005 (64·6%) 11 411 (66·8%) 19 792 (65·2%) 20 716 (66·0%) 5522 (34·7%) 6601 (34·9%)
2 12 305 (62·2%) 11 412 (62·4%) 10 253 (62·1%) 11 080 (62·7%) 19 530 (63·1%) 19 604 (62·6%) 5107 (30·8%) 5782 (29·7%)
3 10 732 (58·6%) 9335 (58·4%) 8911 (58·3%) 9601 (59·4%) 16 571 (59·3%) 16 336 (58·0%) 4316 (26·8%) 4578 (25·0%)
4 7663 (52·0%) 6987 (51·9%) 6535 (50·7%) 7083 (52·9%) 11 902 (53·0%) 11 839 (51·5%) 3104 (21·1%) 3436 (20·4%)
5 (most deprived) 5322 (43·0%) 5316 (42·0%) 4966 (42·4%) 5580 (46·0%) 8433 (44·0%) 8324 (42·6%) 2040 (14·1%) 2198 (13·3%)
Missing IMD score 84 62 152 149 292 303 77 117
GP=general practice. IMD=Index of Multiple Deprivation. *Quintile categories were based on national cutoﬀ s.26
Table 2: Proportions of people who took up screening
Trial 1 (standard 
information and 
gist leaﬂ et)
Trial 2 (standard 
information and 
narrative leaﬂ et)
Trial 3 (GP 
endorsed 
invitation letter)
Trial 4 (enhanced 
reminder letter)
Overall uptake 1·03 (0·99–1·06) 
p=0·15
1·00 (0·96–1·03) 
p=0·80
1·07 (1·04–1·10) 
p<0·0001
1·07 (1·03–1·11) 
p=0·001
1 (least deprived) 1·06 (1·01–1·11) 0·98 (0·93–1·04) 1·04 (0·99–1·08) 1·00 (0·94–1·06)
2 1·02 (0·97–1·07) 1·00 (0·94–1·06) 1·06 (1·02–1·10) 1·04 (0·98–1·11)
3 1·00 (0·94–1·08) 1·05 (0·97–1·13) 1·08 (1·03–1·13) 1·13 (1·06–1·20)
4 1·01 (0·94–1·08) 1·00 (0·94–1·06) 1·09 (1·04–1·15) 1·09 (1·02–1·17)
5 (most deprived) 1·04 (0·96–1·12) 
pinteraction=0·68
0·92 (0·86–0·98) 
pinteraction=0·11
1·07 (1·01–1·13) 
pinteraction=0·49
1·11 (1·04–1·20) 
pinteraction=0·005
Data are odds ratios (95% CI). *Adjusted for hub, age, sex, and screening episode.
Table 3: Adjusted odds for screening uptake, overall and by deprivation quintile
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response times did not diﬀ er by IMD quintile (appendix). 
The proportions of spoilt and undelivered test kits were 
very small and were similar in the two groups and across 
IMD quintiles (appendix).
For trial 2, uptake did not diﬀ er between groups or 
between least and most deprived quintiles (table 2). The 
socioeconomic status gradient in screening uptake did 
not diﬀ er across deprivation quintiles and no eﬀ ect was 
seen on overall uptake (table 3). The median number 
of days to return the test kit was 26 (range 11–126) in the 
intervention group and 26 (10–126) in the control group, 
and timing did not diﬀ er by IMD quintile (appendix). 
The proportions of spoilt and undelivered test kits were 
similar in the two study groups and across IMD quintiles 
(appendix).
In trial 3, general practice endorsement was associated 
with a slight percentage point diﬀ erential in uptake 
between the least and most deprived quintiles (table 2). 
We also noted a slight gradient in uptake related to 
socioeconomic status, but this eﬀ ect was not signiﬁ cant 
(table 3). Although the unadjusted OR indicated little 
eﬀ ect on overall uptake (appendix), the eﬀ ect became 
signiﬁ cant after adjustment (table 3). This change is 
mainly due to diﬀ erences in eﬀ ect sizes between study 
groups for screening episode (table 2). The median 
number of days taken to return the test kit was 22 (range 
8–126) for the intervention group and 23 (11–126) for the 
control group, and timings were similar across IMD 
quintiles (appendix). The proportions of spoilt and 
undelivered test kits were similar in the two study groups 
and across IMD quintiles (appendix).
In trial 4, the enhanced reminder letter was associated 
with a diﬀ erence in uptake between the intervention and 
control groups and the lowest and highest deprivation 
quintiles (table 2). We found a signiﬁ cant interaction 
between uptake and IMD quintile, with a stronger eﬀ ect 
seen in the most deprived than in the least deprived 
quintile (table 3). The unadjusted OR for overall uptake 
did not diﬀ er between study groups, but the eﬀ ect 
became signiﬁ cant after adjustment (table 3). The 
median number of days to return test kits was 11 (range 
–4 to 89) in the intervention group and 11 (0–89) in the 
control group, and did not diﬀ er across IMD quintiles 
(appendix). The proportions of spoilt and undelivered 
test kits also did not diﬀ er (appendix).
Owing to the overlap in timing, the inclusion and 
randomisation statuses of trials 3 and 4 have been cross-
tabulated (appendix). A larger proportion of recipients in 
the trial 3 intervention group was randomised to trial 4 
than in the control group (49·4% vs 44·6%). Nevertheless, 
the unadjusted OR for participation within 4 weeks 
associated with general practice endorsement (before 
the reminder could have been received) was 1·06 (95% 
CI 0·99–1·04), which was higher than that for overall 
uptake (1·03, 0·95–1·11; appendix). Similarly, the 
unadjusted OR associated with the enhanced reminder 
letter for recipients who were not enrolled in trial 3 was 
1·06 (95% CI 0·93–1·21), which is also higher than the 
unadjusted OR for overall uptake (1·04, 0·95–1·14; 
appendix). Furthermore, the OR associated with 
receiving the enhanced reminder letter adjusted for 
trial 3 status was 1·04 (95% CI 0·95–1·14), which 
matched the unadjusted OR.
The average marginal costs of providing the gist and 
narrative leaﬂ ets were, respectively, £0·04 and £0·05 per 
person screened. For the general practice endorsement 
and enhanced reminder letters, a one-oﬀ  cost of £78 000 
was incurred to modify both in the BCSP IT system. As 
this cost would not be incurred again if the interventions 
were implemented, there was no marginal cost per 
person screened.
Discussion
Reducing socioeconomic inequalities in cancer mortality 
is a priority worldwide. Cancer screening is a major 
component of eﬀ orts to bring forward diagnosis to earlier, 
more treatable stages. Even in the UK, where screening 
incurs no ﬁ nancial cost to the individual, uptake declines 
with increasing socioeconomic deprivation.4–6 Our 
four trials enabled assessment of interventions designed 
to lessen inequalities in uptake in large study populations. 
An important strength of ASCEND was that the trials 
were powered to measure the eﬀ ects of interventions in 
relation to socioeconomic status in the total eligible 
population, rather than merely focusing on disadvantaged 
groups. The interventions, therefore, had the potential to 
reach a large number of people who had not previously 
participated in the screening programme. Use of routinely 
collected data enabled us to include most of the potential 
study population in our analysis, except for a very small 
group of people without IMD scores for their postcodes. 
Each intervention was also based on a well established 
rationale and empirical data, and was developed through a 
structured, comprehensive process. Only the enhanced 
reminder letter, however, led to a reduction in the 
socioeconomic status gradient in uptake. The gist and 
narrative leaﬂ et interventions had no eﬀ ect on uptake. 
The general practice endorsed letter was associated with 
increased uptake overall, but did not modify the 
socioeconomic status gradient. None of our interventions 
promoted early response or a reduced number of spoilt 
test kits. The numbers of undelivered information packs 
also did not diﬀ er, by group or IMD quintile.
The gist and narrative leaﬂ ets in trials 1 and 2 were 
designed to make the oﬀ er of screening more visible to 
people with poor literacy skills. Both leaﬂ ets showed this 
potential when their eﬀ ects were assessed on the basis of 
knowledge, attitudes, or intention to participate in 
screening.16,20 A possible explanation for lack of eﬀ ect in 
these trials is that the determinants of intention can 
diﬀ er from the determinants of action, and that the 
leaﬂ ets only aﬀ ected the former. Another possible 
explanation relates to the fact that the two leaﬂ ets had to 
be added to the existing invitation or information rather 
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than being provided as an alternative. Consequently, 
although the leaﬂ ets were designed to be simple, they 
increased the total mass of written material and might 
have undermined the goal of making the screening oﬀ er 
more visible.
The general practice endorsement signiﬁ cantly 
increased overall uptake, but the eﬀ ect size was smaller 
than in many previous studies.10–13 This diﬀ erence was 
probably due to previous studies mostly using letters 
sent directly from the general practitioner or with the 
individual doctors’ signatures on the letters. We were 
unable to apply such alterations for logistical reasons, 
which might have diluted the eﬃ  cacy of this intervention.
Owing to general practice endorsement having 
previously shown eﬀ ects in low-income groups,13 we had 
hypothesised that the eﬀ ect in this study would have 
been stronger in lower than in higher socioeconomic 
groups. Previous studies, however, had not been powered 
to assess eﬀ ects on the socioeconomic gradient. The 
large size of the ASCEND trial, though, means that our 
negative result is deﬁ nitive, at least with the format of 
endorsement that we used. Nevertheless, in view of the 
high level of agreement by practices to endorse the 
screening programme and the absence of a marginal cost 
per person screened, we recommend that the BCSP 
considers adding the general practice endorsement 
banner to screening invitation letters.
One intervention that reduced the socioeconomic 
gradient was the enhanced reminder letter, which also 
slightly increased overall uptake. The aim of this 
intervention was to oﬀ er anyone who had not engaged 
with the original materials an additional opportunity to 
see and consider the screening oﬀ er. Unlike the gist and 
narrative leaﬂ ets, this enhancement was incorporated 
into the one-page reminder letter and, therefore, might 
have had higher visibility. Although the change in the 
gradient was small (as was the eﬀ ect on overall uptake), 
this intervention was also virtually cost-free and, 
therefore, oﬀ ers a practical way for the screening 
programme to reduce the socioeconomic gradient in 
uptake. As this addition to the reminder letter was minor, 
investigating the cost-eﬀ ectiveness of adding a second 
reminder or using alternative channels, such as text 
messaging, to reiterate the oﬀ er of screening could be 
worthwhile.
ASCEND had some limitations. People from deprived 
backgrounds are likely to be struggling with multiple 
social and economic challenges, making it diﬃ  cult for 
them to prioritise cancer screening. These upstream 
issues, however, cannot be addressed by minor variations 
in the format of a screening oﬀ er. Nonetheless, ensuring 
that the screening oﬀ er is not only mailed to all eligible 
adults but is also appropriate for a wide range of levels of 
literacy should be a goal of NHS screening programmes. 
We did not address broader attitudes to cancer. For 
example, cancer fatalism and other negative attitudes are 
more prevalent in groups with low than with high 
socioeconomic status, and fatalism has been associated 
with delayed diagnosis.29 Negative attitudes are not easily 
modiﬁ ed with simple written materials. We did not 
address various other downstream barriers, of which the 
most well established is the unpleasantness associated 
with completing the test kit. If the BCSP implements the 
faecal immunochemical test for haemoglobin, which 
typically only requires one stool sample, inequalities in 
participation might be reduced.30,31
The sampling timeframe for trials 3 and 4 overlapped 
because the original plan had been that individuals 
randomised to receive the general practice endorsement 
letter in trial 3 would have a similar banner on their 
reminder letters in trial 4. This approach, however, was 
logistically impossible because of space limitations on 
the page. Thus, we analysed the two trials separately but 
did supplementary analyses to test whether the overlap 
had resulted in overestimation of eﬀ ects for either 
intervention. We found no evidence of bias and, 
therefore, conclude that the overlap, although not 
desirable, did not compromise our results.
The inclusion of strategies in routine programme 
delivery provides a model for future research, and there 
might be scope to test changes to the interventions that 
could strengthen the eﬀ ects. For instance, supplying all 
the necessary screening information in smaller 
instalments by integrating additional communication 
points into the screening pathway might improve the 
visibility and eﬃ  cacy of the gist and narrative leaﬂ ets. 
The use of additional reminder letters might, through a 
process of elimination, help to target the most deprived 
populations.
In conclusion, the enhanced reminder letter was the 
only strategy to signiﬁ cantly reduce the socioeconomic 
gradient, and overall uptake was only increased by this 
and the general practice endorsement intervention. In 
view of the very low expense, these interventions could 
be implemented with minimum cost or disruption to the 
existing programme. Our ﬁ ndings suggest that tailoring 
of information delivery to the communities being served 
might be useful. A possibility in poor-literacy groups is to 
supplement mailed information with direct contact with 
health professionals. The results of our four trials 
illustrate the diﬃ  culty of addressing inequality in 
screening uptake within an organised programme, but 
highlight the importance of continuing to investigate 
new strategies.
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